| name | Dolasetron |
| classification | 5-HT3 receptor antagonist |
| pharmacokinetics | Dolasetron is primarily metabolized by the liver, and its elimination half-life is approximately 8 hours. The drug is well absorbed after oral administration, with peak plasma concentrations occurring within 1-3 hours. It is mainly excreted in the urine as metabolites. |
| dosage | | adult male 25 70kg | | nausea and vomiting | | dosage | 1-2 mg orally, repeated every 4 to 6 hours, if needed. | | maximum daily dose | 10 mg/day |
|
|
|
| notes | Dosage and frequency may vary based on individual patient response and clinical needs. Consult with a physician or pharmacist for personalized dosing instructions. |
| indications | | 1 | Prevention and treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and post-operative procedures |
|
| safety in pregnancy | | classification | Category B | | details | Animal studies have not shown adverse effects, but adequate and well-controlled studies in pregnant women are lacking. Use only if the potential benefit justifies the potential risk to the fetus. | | notes | Consult with a physician regarding the risks and benefits during pregnancy. |
|
| safety in breastfeeding | | classification | Unknown | | details | It is unknown whether Dolasetron is excreted in human milk. Use of the drug during breastfeeding should only be considered if the benefits outweigh the potential risks to the infant. | | notes | Consult with a physician regarding the risks and benefits during breastfeeding. |
|
| side effects | | 1 | Headache | | 2 | Dizziness | | 3 | Constipation | | 4 | Dry mouth | | 5 | Fatigue | | 6 | Diarrhea | | 7 | Arrhythmias | | 8 | Torsade de pointes (a rare but potentially life-threatening cardiac arrhythmia) | | 9 | Blood pressure changes | | 10 | Jaundice | | 11 | Abdominal pain | | 12 | Confusion | | 13 | Nausea | | 14 | Vomiting |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to Dolasetron or other 5-HT3 receptor antagonists | | 2 | Severe hepatic impairment |
|
| interactions | | 1 | Significant interactions with other medications are possible, including drugs affecting liver enzymes or renal function. Consult with a doctor about concomitant medications or supplement usage. |
|
| warnings and precautions | | 1 | Monitor vital signs, especially blood pressure and ECG, throughout treatment. | | 2 | Caution in patients with pre-existing cardiac conditions. | | 3 | Monitor for signs of liver dysfunction. | | 4 | Patient should be instructed about potential side effects and advised to report any unusual symptoms. |
|
| additional information | | special notes | Dolasetron is associated with increased QT interval and has the potential to cause Torsade de Pointes, especially in patients with pre-existing QT prolongation or other cardiac abnormalities. A thorough medical history and risk assessment is necessary prior to prescribing this medication. |
|
